ASCO submitted a comment letter to the Centers for Medicare & Medicaid Services (CMS) on coverage of next generation sequencing (NGS) for Medicare beneficiaries with advanced cancer.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
CancerLinQ LLC and the Association for Molecular Pathology (AMP), a global, molecular diagnostics professional society, have entered into a collaboration. AMP leadership and members will be applying the breadth of their knowledge to CancerLinQ®, the American Society of Clinical Oncology’s (ASCO) health information technology platform designed to leverage the power of big data to help conquer cancer.
The Oncology Center of Excellence of the Food and Drug Administration is informing health care providers about new safety information for Varubi® (rolapitant) injectable emulsion, a substance P/neurokinin (NK-1) receptor antagonist indicated for the prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults.
On January 12, 2018, the Food and Drug Administration granted regular approval to olaparib tablets (Lynparza® , AstraZeneca Pharmaceuticals LP), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.
On January 12, 2018, the Food and Drug Administration granted approval to afatinib (Gilotrif®, Boehringer Ingelheim Pharmaceutical, Inc.) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
CancerLinQ LLC and the National Society of Genetic Counselors, the professional society for genetic counselors, announced today that they have entered into a strategic alliance.
ASCO sent a letter to CMS to comment on the proposed notice, “Patient Protection and Affordable Care Act; Health and Human Services (HHS) Notice of Benefit and Payment Parameters for 2019” and expressed concerns that it would fundamentally alter many of the consumer and patient protections in individual and small group markets and lead to the establishment of qualified health plans that would fail to address the comprehensive medical needs of patients with cancer.
ASCO submitted comments to the U.S. Food and Drug Administration (FDA) to help guide its newly established Opioid Policy Steering Committee (OPSC). In the comments, ASCO responded to several FDA-posed questions to inform OPSC’s work of effectively addressing the nation-wide opioid crisis.
On February 8-9, 2018, the Solomon Center for Health Law and Policy at Yale Law School will host a free conference, The Policy, Politics & Law of Cancer. This conference will bring together health policy and oncology leaders, including ASCO Chief Medical Officer Dr. Richard Schilsky, who will examine a wide range of policy issues impacting the U.S. cancer care delivery system.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s rule finalizing changes to the Quality Payment Program (QPP) in 2018. ASCO commends CMS for providing relief to physicians impacted by hurricanes in 2017, but urges the agency to remove Part B reimbursement from payment adjustments under the Merit-Based Incentive Payment System (MIPS) and to reconsider the weighting of ASCO quality programs in the MIPS Improvement Activities (IA) category.